Finally, given its role as CMA carrier and its anti-aggregant properties on asyn (Pemberton et al., 2011; Pemberton and Melki, 2012), hsc70 may represent a further potential target for PD therapeutic strategies, but no studies have yet explored such possibility. This evidence concerns the gene HSPA8 and Parkinson disease.